المؤلفون: Assi, M., Martin, S., Wheat, L. J., Hage, C., Freifeld, A., Avery, R., Baddley, J. W., Vergidis, P., Miller, R., Andes, D., Young, J.-A. H., Hammoud, K., Huprikar, S., McKinsey, D., Myint, T., Garcia-Diaz, J., Esguerra, E., Kwak, E. J., Morris, M., Mullane, K. M., Prakash, V., Burdette, S. D., Sandid, M., Dickter, J., Ostrander, D., Antoun, S. A., Kaul, D. R.

المصدر: Clinical Infectious Diseases ; volume 57, issue 11, page 1542-1549 ; ISSN 1058-4838 1537-6591

الاتاحة: http://dx.doi.org/10.1093/cid/cit593
http://academic.oup.com/cid/article-pdf/57/11/1542/869923/cit593.pdf

المؤلفون: Manuel, O., Husain, S., Kumar, D., Zayas, C., Mawhorter, S., Levi, M. E., Kalpoe, J., Lisboa, L., Ely, L., Kaul, D. R., Schwartz, B. S., Morris, M. I., Ison, M. G., Yen-Lieberman, B., Sebastian, A., Assi, M., Humar, A.

المصدر: Clinical Infectious Diseases ; volume 56, issue 6, page 817-824 ; ISSN 1058-4838 1537-6591

الاتاحة: http://dx.doi.org/10.1093/cid/cis993
http://academic.oup.com/cid/article-pdf/56/6/817/17851885/cis993.pdf

المؤلفون: Savona, M R, Newton, D, Frame, D, Levine, J E, Mineishi, S, Kaul, D R

المصدر: Bone Marrow Transplantation ; volume 39, issue 12, page 783-787 ; ISSN 0268-3369 1476-5365

الاتاحة: http://dx.doi.org/10.1038/sj.bmt.1705678
https://www.nature.com/articles/1705678.pdf
https://www.nature.com/articles/1705678

المؤلفون: Cinti, S. K., Kaul, D. R., Sax, P. E., Crane, L. R., Kazanjian, P. H.

المصدر: Clinical Infectious Diseases ; volume 30, issue 3, page 511-514 ; ISSN 1058-4838 1537-6591

الاتاحة: http://dx.doi.org/10.1086/313705
http://academic.oup.com/cid/article-pdf/30/3/511/1634017/30-3-511.pdf

المؤلفون: Kusne, S., Taranto, S., Covington, S., Kaul, D. R., Blumberg, E. A., Wolfe, C., Green, M.

مصطلحات موضوعية: fungal, donors and donation: donor‐derived infections, complication: infectious, antibiotic: antifungal, infectious disease, clinical research/practice, infection and infectious agents, Medicine (General), Health Sciences

وصف الملف: application/pdf

Relation: Kusne, S.; Taranto, S.; Covington, S.; Kaul, D. R.; Blumberg, E. A.; Wolfe, C.; Green, M. (2016). "Coccidioidomycosis Transmission Through Organ Transplantation: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee." American Journal of Transplantation 16(12): 3562-3567.; https://hdl.handle.net/2027.42/134822; American Journal of Transplantation; Carvalho C, Ferreira I, Gaiao S, et al. Cerebral coccidioidomycosis after renal transplantation in a non‐endemic area. Transpl Infect Dis 2010; 12: 151 – 154.; Blodget E, Geiseler PJ, Larsen RA, Stapfer M, Qazi Y, Petrovic LM. Donor‐derived Coccidioides immitis fungemia in solid organ transplant recipients. Transpl Infect Dis 2012; 14: 305 – 310.; Miller MB, Hendren R, Gilligan PH. Posttransplantation disseminated coccidioidomycosis acquired from donor lungs. J Clin Microbiol 2004; 42: 2347 – 2349.; Dierberg KL, Marr KA, Subramanian A, et al. Donor‐derived organ transplant transmission of coccidioidomycosis. Transpl Infect Dis 2012; 14: 300 – 304.; Brugiere O, Forget E, Biondi G, et al. Coccidioidomycosis in a lung transplant recipient acquired from the donor graft in France. Transplantation 2009; 88: 1319 – 1320.; Marsden‐Haug N, et al. Coccidioides immitis identified in soil outside of its known range—Washington, 2013. MMWR Morb Mortal Wkly Rep 2014; 63: 450.; Marsden‐Haug N, Goldoft M, Ralston C, et al. Coccidioidomycosis acquired in Washington State. Clin Infect Dis 2013; 56: 847 – 850.; OPTN/UNOS/DTAC. Recognizing seasonal and geographically endemic infections in organ donors: Considerations during living donor evaluation. 2014 [cited 15 March 2016]. Available from: https//optn.transplant.hrsa.gov/media/1138/seasonal _disease_guidance.pdf.; Kahn A, Carey EJ, Blair JE. Universal fungal prophylaxis and risk of coccidioidomycosis in liver transplant recipients living in an endemic area. Liver Transpl 2015; 21: 353 – 361.; Centers for Disease Control and Prevention. Increase in reported coccidioidomycosis–United States, 1998‐2011. MMWR Morb Mortal Wkly Rep 2013; 62: 217 – 221.; Sondermeyer G, Lee L, Gilliss D, Tabnak F, Vugia D. Coccidioidomycosis‐associated hospitalizations, California, USA, 2000‐2011. Emerg Infect Dis 2013; 19: 1590 – 1597.; Brown J, Benedict K, Park BJ, Thompson GR III. Coccidioidomycosis: Epidemiology. Clin Epidemiol 2013; 5: 185 – 197.; Singh N, Huprikar S, Burdette SD, et al. Donor‐derived fungal infections in organ transplant recipients: Guidelines of the American Society of Transplantation, infectious diseases community of practice. Am J Transplant 2012; 12: 2414 – 2428.; Blair JE, Mulligan DC. Coccidioidomycosis in healthy persons evaluated for liver or kidney donation. Transpl Infect Dis 2007; 9: 78 – 82.; Ison MG, Nalesnik MA. An update on donor‐derived disease transmission in organ transplantation. Am J Transplant 2011; 11: 1123 – 1130.; Garzoni C, Ison MG. Uniform definitions for donor‐derived infectious disease transmissions in solid organ transplantation. Transplantation 2011; 92: 1297 – 1300.; Wright PW, Pappagianis D, Wilson M, et al. Donor‐related coccidioidomycosis in organ transplant recipients. Clin Infect Dis 2003; 37: 1265 – 1269.; Uttam T, Yung GL, Kriett JM, et al. Donor transfer of pulmonary coccidioidomycosis in lung transplantation. Ann Thorac Surg 2002; 73: 306 – 308.

الاتاحة: https://hdl.handle.net/2027.42/134822
https://doi.org/10.1111/ajt.13950

المؤلفون: Beaird, O E, Freifeld, A, Ison, M G, Lawrence, S J, Theodoropoulos, N, Clark, N M, Razonable, R R, Alangaden, George, Miller, R, Smith, J, Young, J AH, Hawkinson, D, Pursell, K, Kaul, D R

المصدر: Internal Medicine Articles

مصطلحات موضوعية: Administration, Oral, Antiviral Agents, Data Collection, Humans, Immunocompromised Host, Immunoglobulins, Intravenous, Organ Transplantation, Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus, Human, Respiratory Therapy, Ribavirin

Relation: https://scholarlycommons.henryford.com/internalmedicine_articles/122; http://sfxhosted.exlibrisgroup.com/hfhs?sid=Entrez:PubMed&id=pmid:26923867

الاتاحة: https://scholarlycommons.henryford.com/internalmedicine_articles/122
http://sfxhosted.exlibrisgroup.com/hfhs?sid=Entrez:PubMed&id=pmid:26923867

المؤلفون: Kaul, D. R., Mehta, A. K., Wolfe, C. R., Blumberg, E., Green, M.

مصطلحات موضوعية: Medicine (General), Health Sciences

وصف الملف: application/pdf

Relation: Kaul, D. R.; Mehta, A. K.; Wolfe, C. R.; Blumberg, E.; Green, M. (2015). "Ebola Virus Disease: Implications for Solid Organ Transplantation." American Journal of Transplantation 15(1): 5-6.; http://hdl.handle.net/2027.42/109839; American Journal of Transplantation; Fischer SA, Graham MB, Kuehnert MJ, Kotton CN, Srinivasan A, Marty FM, et al. Transmission of lymphocytic choriomeningitis virus by organ transplantation. N Engl J Med 2006; 354: 2235 – 2249.; Risk of transmission of Ebola viurs via donated blood and other substances of human origin in the EU. European Center for Disease Prevention and Control; October 6, 2014.; Leroy EM, Baize S, Volchkov VE, et al. Human asymptomatic Ebola infection and strong inflammatory response. Lancet 2000; 355: 2210 – 2215.; Bausch DG, Towner JS, Dowell SF, et al. Assessment of the risk of Ebola virus transmission from bodily fluids and fomites. J Infect Dis 2007; 196: S142 – 147.; Transplant Pro: Guidance Regarding Ebola Virus Disease (EVD). 2014. Available at: http://transplantpro.org/guidance‐regarding‐ebola‐virus‐disease‐evd/. Accessed October 21, 2014.; Centers for Disease Control and Prevention: Ebola (Ebola Virus Disease); 2014 Outbreak in West Africa. 2014. Available at: http://www.cdc.gov/vhf/ebola/outbreaks/2014‐west‐africa/index.html. Accessed October 21, 2014.

الاتاحة: http://hdl.handle.net/2027.42/109839
https://doi.org/10.1111/ajt.13093

المؤلفون: Kaul, D. R., Davis, J. A.

مصطلحات موضوعية: Leukemia, Screening, Human T Lymphotrophic Virus, Donor‐To‐Host Transmission, Medicine (General), Health Sciences

وصف الملف: application/pdf

Relation: Kaul, D. R.; Davis, J. A. (2013). "Human T Cell Lymphotrophic Virus 1/2 in Solid Organ Transplantation." American Journal of Transplantation 13(s4): 355-360.; http://hdl.handle.net/2027.42/97196; American Journal of Transplantation; Huang RC, Fishman JA. Screening of deceased organ donors: No easy answers. Transplantation 2011; 91: 146 – 149.; Lee TH, Chafets DM, Busch MP, Murphy EL. Quantitation of HTLV‐I and II proviral load using real‐time quantitative PCR with SYBR Green chemistry. J Clin Virol 2004; 31: 275 – 282.; Package Insert: Abbott HTLV‐I/HTLV‐II EIA.; Gout O, Gessain A, Iba‐Zizen M, et al. The effect of zidovudine on chronic myelopathy associated with HTLV‐1. J Neurol 1991; 238: 108 – 109.; Martin F, Taylor GP. Prospects for the management of human T‐cell lymphotropic virus type 1‐associated myelopathy. AIDS Rev 2011; 13: 161 – 170.; Sheremata WA, Benedict D, Squilacote DC, Sazant A, DeFreitas E. High‐dose zidovudine induction in HTLV‐I‐associated myelopathy: Safety and possible efficacy. Neurology 1993; 43: 2125 – 2129.; Taylor GP, Goon P, Furukawa Y, Green H, Barfield A, Mosley A, et al. Zidovudine plus lamivudine in human T‐lymphotropic virus type‐I‐associated myelopathy: A randomised trial. Retrovirology 2006; 3: 63 – 71.; Treviño A, Parra P, Bar‐Magen T, Garrido C, de Mendoza C, Soriano V. Antiviral effect of raltegravir on HTLV‐1 carriers. J Antimicrobial Chemother 2012; 67: 218 – 221.; Food and Drug Administration. 2012; Available at: www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/licensedProductsBLAs/BloodDonorScreening/InfectiousDisease/ucm090707.htm. Accessed May 15, 2012.; Grassi MFR, Olavarria VN, Kruschewsky RdA, et al. Human T cell lymphotropic virus type 1 (HTLV‐1) proviral load of HTLV‐associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients according to new diagnostic criteria of HAM/TSP. J Med Virol 2011; 83: 1269 – 1274.; Silva MT, Harab RC, Leite AC, Schor D, Araujo A, Andrada‐Serpa MJ. Human T lymphotropic virus type 1 (HTLV‐1) proviral load in asymptomatic carriers, HTLV‐1‐associated myelopathy/tropical spastic paraparesis, and other neurological abnormalities associated with HTLV‐1 infection. Clin Infect Dis 2007; 44: 689 – 692.; Goncalves DU, Proietti FA, Ribas JG, et al. Epidemiology, treatment, and prevention of human T‐cell leukemia virus type 1‐associated diseases. Clin Microbiol Rev 2010; 23: 577 – 589.; Kataoka R, Takehara N, Iwahara Y, et al. Transmission of HTLV‐I by blood transfusion and its prevention by passive immunization in rabbits. Blood 1990; 76: 1657 – 1661.; Menna‐Barreto M. HTLV‐II transmission to a health care worker. Am J Infect Control 2006; 34: 158 – 160.; Amin RM, Jones B, Rubert M, et al. Risk of retroviral infection among retrovirology laboratory and health care workers. American Society for Microbiology 92nd General Meeting, New Orleans, Louisiana, May 26 – 30, 1992. (abstract T‐20).; Electronic Therapeutic Guidelines. Available at: http://www.tg.org.au/etg_demo/tgc/abg/4651.htm#4703ID_GL. Accessed May 15, 2012.; Seegulam ME, Ratner L. Integrase inhibitors effective against human T‐cell leukemia virus type 1. Antimicrob Agents Chemother 2011; 55: 2011 – 2017.; Haynes RA, 2nd, Ware E, Premanandan C, et al. Cyclosporine‐induced immune suppression alters establishment of HTLV‐1 infection in a rabbit model. Blood 2010; 115: 815 – 823.; Blattner WA, Saxinger C, Riedel D, et al. A study of HTLV‐I and its associated risk factors in Trinidad and Tobago. J Acquir Immune Defic Syndr 1990; 3: 1102 – 1108.; Proietti FA, Carneiro‐Proietti AB, Catalan‐Soares BC, Murphy EL. Global epidemiology of HTLV‐I infection and associated diseases. Oncogene 2005; 24: 6058 – 6068.; Glynn SA, Kleinman SH, Schreiber GB, et al. Trends in incidence and prevalence of major transfusion‐transmissible viral infections in US blood donors, 1991 to 1996. Retrovirus Epidemiology Donor Study (REDS). JAMA 2000; 284: 229 – 235.; Claquin J, Romano P, Noury D, et al. Human T lymphotropic virus 1–2 positive antibodies in potential organ donors in France. Transplant Proc 1996; 28: 189 – 190.; Kaul DR, Taranto S, Alexander C, et al. Donor screening for human T‐cell lymphotrophic virus 1/2: Changing paradigms for changing testing capacity. Am J Transplant 2010; 10: 207 – 213.; Manns A, Wilks RJ, Murphy EL, et al. A prospective study of transmission by transfusion of HTLV‐I and risk factors associated with seroconversion. Int J Cancer 1992; 51: 886 – 891.; Martin‐Davila P, Fortun J, Lopez‐Velez R, et al. Transmission of tropical and geographically restricted infections during solid‐organ transplantation. Clin Microbiol Rev 2008; 21: 60 – 96.; Murphy E, Roucoux D. The epidemiology and disease outcomes of human T‐lymphotropic virus type II. AIDS Rev 2004; 6: 144 – 154.; Nakamura N, Tamaru S, Ohshima K, Tanaka M, Arakaki Y, Miyauchi T. Prognosis of HTLV‐I‐positive renal transplant recipients. Transplant Proc 2005; 37: 1779 – 1782.; Tanabe K, Kitani R, Takahashi K, et al. Long‐term results in human T‐cell leukemia virus type 1‐positive renal transplant recipients. Transplant Proc 1998; 30: 3168 – 3170.; Shirai H, Suzuki M, Tomita Y, et al. Renal transplantation in patients with human T‐cell lymphotropic virus type 1. Transplant Proc 2012; 44: 83 – 86.; Hoshida Y, Li T, Dong Z, et al. Lymphoproliferative disorders in renal transplant patients in Japan. Intl J Cancer 2001; 91: 869 – 875.; Yoshizumi T, Shirabe K, Ikegami T, et al. Impact of human T cell leukemia virus type 1 in living donor liver transplantation. Am J Transplant 2012; 12: 1479 – 1485.; Marvin MR, Brock GN, Kwarteng K, et al. Increasing utilization of human T‐cell lymphotropic virus (+) donors in liver transplantation: Is it safe? Transplantation 2009; 87: 1180 – 1190.; Shames BD, D'Alessandro AM, Sollinger HW. Human T‐cell lymphotrophic virus infection in organ donors: A need to reassess policy? Am J Transplant 2002; 2: 658 – 663.; Remesar MC, del Pozo AE, Pittis MG, Mangano AM, Sen L, Briones L. Transmission of HTLV‐I by kidney transplant. Transfusion 2000; 40: 1421 – 1422.; Toro C, Benito R, Aguilera A, et al. Infection with human T lymphotropic virus type I in organ transplant donors and recipients in Spain. J Med Virol 2005; 76: 268 – 270.; Yara S, Fujita J, Date H. Transmission of human T‐lymphotropic virus type I by bilateral living‐donor lobar lung transplantation. J Thorac Cardiovasc Surg 2009; 138: 255 – 256.; Nakamura N, Arakaki Y, Sunagawa H, et al. Influence of immunosuppression in HTLV‐1‐positive renal transplant recipients. Transplant Proc 1998; 30: 1324 – 1326.; Gout O, Baulac M, Gessain A, et al. Rapid development of myelopathy after HTLV‐I infection acquired by transfusion during cardiac transplantation. N Engl J Med 1990; 322: 383 – 388.

الاتاحة: http://hdl.handle.net/2027.42/97196
https://doi.org/10.1111/ajt.12127

المؤلفون: Kaul, D. R.

المساهمون: Department of Internal Medicine, Division of Infectious Disease, University of Michigan Medical School, Ann Arbor, MI

مصطلحات موضوعية: Medicine (General), Health Sciences

وصف الملف: application/pdf

Relation: Kaul, D. R. (2012). "Human T Cell Lymphotrophic Virus 1 After Transplantation: What Is the Risk of Recipient Disease?." American Journal of Transplantation 12(6).; http://hdl.handle.net/2027.42/92115; American Journal of Transplantation; Tanabe K, Kitani R, Takahashi K, et al. Long‐term results in human T‐cell leukemia virus type 1‐positive renal transplant recipients. Transplant Proc 1998; 30: 3168 – 3170.; Kaul DR, Taranto S, Alexander C, et al. Donor screening for human T‐cell lymphotrophic virus 1/2: Changing paradigms for changing testing capacity. Am J Transplant 2010; 10: 207 – 213.; Yoshizumi T, Shirabe K, Ikegami T, et al. Impact of human T‐cell leukemia virus type 1 in living donor liver transplantation. Am J Transplant 2012; 12: 1479 – 1485.; Toro C, Rodés B, Poveda E, Soriano V. Rapid development of subacute myelopathy in three organ transplant recipients after transmission of human T‐cell lymphotropic virus type I from a single donor. Transplantation 2003; 75: 102 – 104.; Hoshida Y, Li T, Dong Z, et al. Lymphoproliferative disorders in renal transplant patients in Japan. Int J Cancer 2001; 91: 869 – 875.

الاتاحة: http://hdl.handle.net/2027.42/92115
https://doi.org/10.1111/j.1600-6143.2012.04041.x

المؤلفون: Anand, S., Samaniego, Millie D., Kaul, D. R.

مصطلحات موضوعية: P Neumocystis Jirovecii Pneumonia, PCP, N Ocardia, Renal Transplantation, Trimethoprim–Sulfamethoxazole, Medicine (General), Microbiology and Immunology, Health Sciences

وصف الملف: application/pdf

Relation: Anand, S.; Samaniego, M.; Kaul, D.R. (2011). " P neumocystis jirovecii pneumonia is rare in renal transplant recipients receiving only one month of prophylaxis." Transplant Infectious Disease 13(6): 570-574.; https://hdl.handle.net/2027.42/89470; Transplant Infectious Disease; Fishman JA. Prevention of infection caused by Pneumocystis carinii in transplant recipients. Clin Infect Dis 2001; 33 ( 8 ): 1397 – 1405.; Martin SI, Fishman JA. Pneumocystis pneumonia in solid organ transplant recipients. Am J Transplant 2009; 9 ( Suppl 4 ): S227 – S233.; EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long‐term management of the transplant recipient. IV.7.1 Late infections. Pneumocystis carinii pneumonia. Nephrol Dial Transplant 2002; 17 ( Suppl 4 ): 36 – 39.; Clark NM. Nocardia in solid organ transplant recipients. Am J Transplant 2009; 9 ( Suppl 4 ): S70 – S77.; Gordon SM, LaRosa SP, Lamadi S, et al. Should prophylaxis for Pneumocystis carinii pneumonia in solid organ transplant recipients ever be discontinued? Clin Infect Dis 1999; 28 ( 2 ): 240 – 246.; Neff RT, Jindal RM, Yoo DY, Hurst FP, Agodoa LY, Abbott KC. Analysis of USRDS: incidence and risk factors for Pneumocystis jiroveci pneumonia. Transplantation 2009; 88 ( 1 ): 135 – 141.; Peleg AY, Husain S, Qureshi ZA, et al. Risk factors, clinical characteristics, and outcome of Nocardia infection in organ transplant recipients: a matched case‐control study. Clin Infect Dis 2007; 44 ( 10 ): 1307 – 1314.; Batiuk TD, Bodziak KA, Goldman M. Infectious disease prophylaxis in renal transplant patients: a survey of US transplant centers. Clin Transplant 2002; 16 ( 1 ): 1 – 8.; Arend SM, Westendorp RG, Kroon FP, et al. Rejection treatment and cytomegalovirus infection as risk factors for Pneumocystis carinii pneumonia in renal transplant recipients. Clin Infect Dis 1996; 22 ( 6 ): 920 – 925.; Radisic M, Lattes R, Chapman JF, et al. Risk factors for Pneumocystis carinii pneumonia in kidney transplant recipients: a case‐control study. Transpl Infect Dis 2003; 5 ( 2 ): 84 – 93.; de Boer MG, Bruijnesteijn van Coppenraet LE, Gaasbeek A, et al. An outbreak of Pneumocystis jiroveci pneumonia with 1 predominant genotype among renal transplant recipients: interhuman transmission or a common environmental source? Clin Infect Dis 2007; 44 ( 9 ): 1143 – 1149.; Gianella S, Haeberli L, Joos B, et al. Molecular evidence of interhuman transmission in an outbreak of Pneumocystis jirovecii pneumonia among renal transplant recipients. Transpl Infect Dis 2010; 12 ( 1 ): 1 – 10.; Rabodonirina M, Vanhems P, Couray‐Targe S, et al. Molecular evidence of interhuman transmission of Pneumocystis pneumonia among renal transplant recipients hospitalized with HIV‐infected patients. Emerg Infect Dis 2004; 10 ( 10 ): 1766 – 1773.; Schmoldt S, Schuhegger R, Wendler T, et al. Molecular evidence of nosocomial Pneumocystis jirovecii transmission among 16 patients after kidney transplantation. J Clin Microbiol 2008; 46 ( 3 ): 966 – 971.; Yazaki H, Goto N, Uchida K, Kobayashi T, Gatanaga H, Oka S. Outbreak of Pneumocystis jiroveci pneumonia in renal transplant recipients: P. jiroveci is contagious to the susceptible host. Transplantation 2009; 88 ( 3 ): 380 – 385.; Fox BC, Sollinger HW, Belzer FO, Maki DG. A prospective, randomized, double‐blind study of trimethoprim‐sulfamethoxazole for prophylaxis of infection in renal transplantation: clinical efficacy, absorption of trimethoprim‐sulfamethoxazole, effects on the microflora, and the cost‐benefit of prophylaxis. Am J Med 1990; 89 ( 3 ): 255 – 274.; Hibberd PL, Tolkoff‐Rubin NE, Doran M, et al. Trimethoprim‐sulfamethoxazole compared with ciprofloxacin for the prevention of urinary tract infection in renal transplant recipients. A double‐blind, randomized controlled trial. Online J Curr Clin Trials 1992 Aug 11, Doc No 15.; Oz HS, Hughes WT. Novel anti‐ Pneumocystis carinii effects of the immunosuppressant mycophenolate mofetil in contrast to provocative effects of tacrolimus, sirolimus, and dexamethasone. J Infect Dis 1997; 175 ( 4 ): 901 – 904.; Placebo‐controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. Lancet 1995; 345 ( 8961 ): 1321 – 1325.; A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 1996; 61 ( 7 ): 1029 – 1037.; Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995; 60 ( 3 ): 225 – 232.; Ponce CA, Gallo M, Bustamante R, Vargas SL. Pneumocystis colonization is highly prevalent in the autopsied lungs of the general population. Clin Infect Dis 2010; 50 ( 3 ): 347 – 353.; Calderón EJ. Pneumocystis infection: seeing beyond the tip of the iceberg. Clin Infect Dis 2010; 50 ( 3 ): 354 – 356.; Kotton CN, Lattes R. Parasitic infections in solid organ transplant recipients. Am J Transplant 2009; 9 ( Suppl 4 ): S234 – S251.

الاتاحة: https://hdl.handle.net/2027.42/89470
https://doi.org/10.1111/j.1399-3062.2011.00692.x

المؤلفون: Kaul, D. R., Taranto, S. E., Alexander, C., Covington, S., Marvin, M., Nowicki, M., Orlowski, J. P., Pancoska, C., Pruett, Timothy L., Ison, Michael G.

المساهمون: Department of Internal Medicine, Division of Infectious Diseases, University of Michigan Medical School, Ann Arbor, MI, United Network for Organ Sharing, Richmond, VA, Living Legacy Foundation of MD, Baltimore, MD, Department of Surgery, Division of Transplantation, Jewish Hospital, Louisville, KY, National Institute of Transplantation, Los Angeles, CA, Center for Donation and Transplant, Albany, NY, LABS-Inc., Centennial, CO, Department of Surgery, Division of Transplantation, University of Virginia Health Systems, Charlottesville, VA, Department of Medicine, Division of Infectious Diseases and Department of Surgery, Division of Organ Transplantation, Feinberg School of Medicine, Northwestern University, Chicago, IL

مصطلحات موضوعية: Donor Evaluation, Donor-to-Host Transmission, Infectious Diseases, Viral Infection, Medicine (General), Health Sciences

وصف الملف: 82587 bytes; 3109 bytes; application/pdf; text/plain

Relation: Kaul, D. R.; Taranto, S.; Alexander, C.; Covington, S.; Marvin, M.; Nowicki, M.; Orlowski, J.; Pancoska, C.; Pruett, T. L.; Ison, M. G. (2010). "Donor Screening for Human T-cell Lymphotrophic Virus 1/2: Changing Paradigms for Changing Testing Capacity." American Journal of Transplantation 10(2): 207-213.; https://hdl.handle.net/2027.42/74865; http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=19839982&dopt=citation; American Journal of Transplantation; Blattner WA, Saxinger C, Riedel D et al. A study of HTLV-I and its associated risk factors in Trinidad and Tobago. J Acquir Immune Defic Syndr 1990; 3: 1102 – 1108.; Glynn SA, Kleinman SH, Schreiber GB et al. Trends in incidence and prevalence of major transfusion-transmissible viral infections in U.S. blood donors, 1991 to 1996. Retrovirus Epidemiology Donor Study (REDS). JAMA 2000; 284: 229 – 235.; Manns A, Wilks RJ, Murphy EL et al. A prospective study of transmission by transfusion of HTLV-I and risk factors associated with seroconversion. Int J Cancer 1992; 51: 886 – 891.; Martin-Davila P, Fortun J, Lopez-Velez R et al. Transmission of tropical and geographically restricted infections during solid-organ transplantation. Clin Microbiol Rev 2008; 21: 60 – 96.; Murphy E, Roucoux D. The epidemiology and disease outcomes of human T-lymphotropic virus type II. AIDS Rev 2004; 6: 144 – 154.; Nowicki MJ, Matsuoka L, Brucal D et al. High seroprevalence of anti-HTLV-I/II antibodies among solid organ donors necessitates confirmatory testing. Transplantation 2006; 82: 1210 – 1213.; Shames BD, D'Alessandro AM, Sollinger HW. Human T-cell lymphotrophic virus infection in organ donors: A need to reassess policy? Am J Transplant 2002; 2: 658 – 663.; 8. U.S. Department of Health and Human Services. Organ Procurement and Transplantation Network. Available from: http://optn.transplant.hrsa.gov/policiesAndBylaws/policies.asp. Accessed April 23, 2009.; 9. US Food and Drug Administrations. Center for Biologics Evaluation and Research. [cited 2009 April 24]; Available from: http://www.fda.gov/cber/tissue/prod.htm#approved; Ison MG, Pruett T, Teperman L. Current practices and future challenges: A survey reported by the OPTN/UNOS Ad Hoc Disease Transmission Advisory Committee. In: American Transplantation Congress: 385 Abstract. Boston, 2009.; 11. Package Insert: Abbott PRISM HTLV-II/HTLV-II.; 12. Package Insert: Abbott HTLV-I/HTLV-II EIA.; 13. Package Insert: BioMerieux Vironostika HTLV-I/II Microelisa System.; Nakatsuji Y, Sugai F, Watanabe S et al. HTLV-I-associated myelopathy manifested after renal transplantation. J Neurol Sci 2000; 177: 154 – 156.; Remesar MC, del Pozo AE, Pittis MG, Mangano AM, Sen L, Briones L. Transmission of HTLV-I by kidney transplant. Transfusion 2000; 40: 1421 – 1422.; Toro C, RodÉs B, Poveda E, Soriano V. Rapid development of subacute myelopathy in three organ transplant recipients after transmission of human T-cell lymphotropic virus type I from a single donor. Transplantation 2003; 75: 102 – 104.; Hoshida Y, Li T, Dong Z et al. Lymphoproliferative disorders in renal transplant patients in Japan. Int J Cancer 2001; 91: 869 – 875.; Kawano N, Shimoda K, Ishikawa F et al. Adult T-cell leukemia development from a human T-cell leukemia virus type I carrier after a living-donor liver transplantation. Transplantation 2006; 82: 840 – 843.; Nakamura N, Arakaki Y, Sunagawa H et al. Influence of immunosuppression in HTLV-1-positive renal transplant recipients. Transpl Proc 1998; 30: 1324 – 1326.; Tanabe K, Kitani R, Takahashi K et al. Long-term results in human T-cell leukemia virus type 1-positive renal transplant recipients. Transpl Proc 1998; 30: 3168 – 3170.; Marvin MR, Brock GN, Kwarteng K et al. Increasing utilization of human T-cell lymphotropic virus (+) donors in liver transplantation: Is it safe? Transplantation 2009; 87: 1180 – 1190.; Claquin J, Romano P, Noury D et al. Human T lymphotropic virus 1--2 positive antibodies in potential organ donors in France. Transpl Proc 1996; 28: 189 – 190.; Toro C, Benito R, Aguilera A et al. Infection with human T lymphotropic virus type I in organ transplant donors and recipients in Spain. J Med Virol 2005; 76: 268 – 270.; Harrington WJ Jr., Ucar A, Gill P et al. Clinical spectrum of HTLV-I in south Florida. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 8: 466 – 473.; Levine PH, Dosik H, Joseph EM et al. A study of adult T-cell leukemia/lymphoma incidence in central Brooklyn. Int J Cancer 1999; 80: 662 – 666.; 26. Personal communication, National Institute of Transplantation, Inc., 2009.; 27. Personal communication, Carol Pancoska, LABS-Inc., 2009.; Nakamura N, Tamaru S, Ohshima K, Tanaka M, Arakaki Y, Miyauchi T. Prognosis of HTLV-I-positive renal transplant recipients. Transpl Proc 2005; 37: 1779 – 1782.

الاتاحة: https://hdl.handle.net/2027.42/74865
http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=19839982&dopt=citation
https://doi.org/10.1111/j.1600-6143.2009.02867.x

المؤلفون: Peres, E., Khaled, Y., Krijanovski, O. I., Mineishi, S., Levine, John E., Kaul, D. R., Riddell, James

المساهمون: Blood and Marrow Transplant Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, USA , and, Division of Infectious Diseases, University of Michigan Medical School, Ann Arbor, Michigan, USA

مصطلحات موضوعية: Stem Cell Transplant, Non-tuberculous Mycobacterium, Pneumonia, Tigecycline, Mycobacterium Chelonae, Medicine (General), Microbiology and Immunology, Health Sciences

وصف الملف: 419421 bytes; 3109 bytes; application/pdf; text/plain

Relation: Peres, E.; Khaled, Y.; Krijanovski, O.I.; Mineishi, S.; Levine, J.E.; Kaul, D.R.; Riddell, J. (2009). " Mycobacterium chelonae necrotizing pneumonia after allogeneic hematopoietic stem cell transplant: report of clinical response to treatment with tigecycline." Transplant Infectious Disease 11(1): 57-63.; https://hdl.handle.net/2027.42/74115; http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=18983415&dopt=citation; Transplant Infectious Disease; Weinstock D, Feinstein M, Sepkowitz K, Jakubowski A. High rates of infection and colonization by nontuberculous mycobacteria after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2003; 31: 1015 – 1021.; Roy V, Weisdorf D. Mycobacterial infections following bone marrow transplantation: a 20 year retrospective review. Bone Marrow Transplant 1997; 19: 467 – 470.; Gaviria J, Garcia P, Garrido S, Corey L, Boeckh M. Nontuberculous mycobacterial infections in hematopoietic stem cell transplant recipients: characteristics of respiratory and catheter-related infections. Biol Blood Marrow Transplant 2000; 6: 361 – 369.; Cordonnier C, Martino R, Trabasso P, et al. Mycobacterial infection: a difficult and late diagnosis in stem cell transplant recipients. Clin Infect Dis 2002; 38: 1229 – 1236.; Field S, Cowie R. Lung disease due to the more common nontuberculous mycobacteria. Chest 2006; 129: 1653 – 1672.; Jacobson K, Garcia R, Libshitz H, et al. Clinical and radiological features of pulmonary disease caused by rapidly growing mycobacteria in cancer patients. Eur J Clin Microbiol Infect Dis 1998; 17: 615 – 621.; Kourbeti I, Maslow M. Nontuberculous mycobacterial infections of the lung. Curr Infect Dis Rep 2000; 2: 193 – 200.; Griffith D, Aksamit T, Brown-Elliott B, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175: 367 – 416.; Falkingham J 3rd. Nontuberculous mycobacteria in the environment. Clin Chest Med 2002; 23: 529 – 551.; Au W, Cheng V, Ho P, et al. Nontuberculous mycobacterial infections in Chinese hematopoietic stem cell transplantation recipients. Bone Marrow Transplant 2003; 32: 709 – 714.; Kurzrock R, Zander A, Vellekoop L, Kanojia M, Luna M, Dicke K. Mycobacterial pulmonary infections after allogeneic bone marrow transplantation. Am J Med 1984; 77: 35 – 40.; Navari R, Sullivan K, Springmeyer S, et al. Mycobacterial infections in marrow transplant patients. Transplantation 1983; 36: 509 – 513.; Doucette K, Fishman J. Nontuberculous mycobacterial infection in hematopoietic stem cell and solid organ transplant recipients. Clin Infect Dis 2004; 38: 1428 – 1439.; Bodle EE, Cunningham JA, Della-Latta P, Schluger NW, Saiman L. Epidemiology of nontuberculous mycobacteria in patients without HIV infection, New York City. Emerg Infect Dis 2008; 14: 390 – 396.; Hazelton T, Newell J Jr, Cook J, Huitt G, Lynch D. CT findings in 14 patients with Mycobacterium chelonae pulmonary infection. Am J Roentgenol 2000; 175: 413 – 416.; De Groote M, Huitt G. Infections due to rapidly growing mycobacteria. Clin Infect Dis 2006; 42: 1756 – 1763.; 17. NCCLS. Susceptibility testing of Mycobacteria, Nocardiae, and other aerobic Actinomyctes; approved standard. NCCLS 2003; M24 A.; Tartaglione T. Treatment of nontuberculous mycobacterial infections: role of clarithromycin and azithromycin. Clin Ther 1997; 19: 626 – 638.; Vemulapalli R, Cantey J, Steed L, Knapp T, Thielman N. Emergence of resistance to clarithromycin during treatment of disseminated cutaneous Mycobacterium chelonae infection: case report and literature review. J Infect 2001; 43: 163 – 168.; Brown-Elliott B, Wallace R Jr, Blinkhorn R, Crist C, Mann L. Successful treatment of disseminated Mycobacterium chelonae infection with linezolid. Clin Infect Dis 2001; 33: 1433 – 1434.; Wallace R Jr, Brown-Elliott B, Ward S, Crist C, Mann L, Wilson R. Activities of linezolid against rapidly growing mycobacteria. Antimicrob Agents Chemother 2001; 45: 764 – 767.; Wallace R Jr, Brown-Elliott B, Crist C, Mann L, Wilson R. Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline and doxycycline against isolates of nontuberculous mycobacteria. Antimicrob Agents Chemother 2002; 46: 3164 – 3167.; 23. Wyeth Pharmaceuticals. Tigecycline package insert (data on file).; Testa R, Petersen P, Jacobus N, Sum P-E, Lee V, Tally F. In vitro and in vivo antibacterial activities of the glycylcycline class of semisynthetic tetracyclines. Antimicrob Agents Chemother 1993; 37: 2270 – 2277.; de Silva T, Cope A, Goepel J, Greig J. The use of adjuvant granulocyte-macrophage colony-stimulating factor in HIV-related disseminated atypical mycobacterial infection. J Infect 2007; 54: e207 – e210.; Marshall S. Technology insight: ECP for the treatment of GvHD – can we offer selective immune control without generalized immunosuppression? Nat Clin Pract Oncol 2006; 3: 302 – 314.; Adams L, Gillis T, Hwang D, Krahenbuhl J. Effects of essential fatty acid deficiency on prostaglandin E2 production and cell-mediated immunity in a mouse model of leprosy. Infect Immun 1997; 65: 1152 – 1157.; Bahr G, Rook G, Stanford J. Prostaglandin-dependent regulation of in vitro proliferative response to mycobacterial antigens of peripheral blood lymphocytes from normal donors and from patients with tuberculosis or leprosy. Clin Exp Immunol 1981; 45: 646 – 653.; Venkataprasad N, Shiratsuchi H, Johnson J, Ellner J. Induction of prostaglandin E2 by human monocytes infected with Mycobacterium avium complex – modulation of cytokine expression. J Infect Dis 1996; 174: 806 – 811.; Singh N, Yu V. Successful treatment of pulmonary infection due to Mycobacterium chelonae: case report and review. Clin Infect Dis 1992; 14: 156 – 161.

الاتاحة: https://hdl.handle.net/2027.42/74115
http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=18983415&dopt=citation
https://doi.org/10.1111/j.1399-3062.2008.00351.x

المؤلفون: Shanahan, A., Malani, Preeti N., Kaul, D. R.

المساهمون: Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA, Division of Infectious Diseases, University of Michigan Medical School, Ann Arbor, Michigan, USA, Geriatric Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan, USA, Geriatric Research Education and Clinical Center (GRECC), Ann Arbor, Michigan, USA

مصطلحات موضوعية: CMV Infection, Cytomegalovirus, Solid Organ Transplantation, CMV Relapse, Medicine (General), Microbiology and Immunology, Health Sciences

وصف الملف: 119150 bytes; 3109 bytes; application/pdf; text/plain

Relation: Shanahan, A.; Malani, P.N.; Kaul, D.R. (2009). "Relapsing cytomegalovirus infection in solid organ transplant recipients." Transplant Infectious Disease 11(6): 513-518.; https://hdl.handle.net/2027.42/73013; http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=19735385&dopt=citation; Transplant Infectious Disease; Allice T, Enrietto M, Pittaluga F, et al. Quantitation of cytomegalovirus DNA by real-time polymerase chain reaction in peripheral blood specimens of patients with solid organ transplants: comparison with end-point PCR and pp65 antigen test. J Med Virol 2006; 78 ( 7 ): 915 – 922.; Lopau K, Greser A, Wanner C. Efficacy and safety of preemptive anti-CMV therapy with valganciclovir after kidney transplantation. Clin Transplant 2007; 21 ( 1 ): 80 – 85.; Falagas ME, Snydman DR, Griffith J, Werner BG, Freeman R, Rohrer R. Clinical and epidemiological predictors of recurrent cytomegalovirus disease in orthotopic liver transplant recipients. Clin Infect Dis 1997; 25 ( 2 ): 314 – 317.; Franco A, Serrano R, Gimeno A, et al. [ Evaluation of viral load and antigenemia as markers for relapse cytomegalovirus infection in renal transplant recipients.] NefrologÍa 2007; 27 ( 2 ): 202 – 208.; Humar A, Kumar D, Boivin G, Caliendo AM. Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease. J Infect Dis 2002; 186 ( 6 ): 829 – 833.; Levitsky J, Freifeld AG, Puumala S, et al. Cytomegalovirus viremia in solid organ transplantation: does the initial viral load correlate with risk factors and outcomes? Clin Transplant 2008; 22 ( 2 ): 222 – 228.; Sia IG, Wilson JA, Groettum CM, Espy MJ, Smith TF, Paya CV. Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation. J Infect Dis 2000; 181 ( 2 ): 717 – 720.; Turgeon N, Fishman JA, Doran M, et al. Prevention of recurrent cytomegalovirus disease in renal and liver transplant recipients: effect of oral ganciclovir. Transpl Infect Dis 2000; 2 ( 1 ): 2 – 10.; Preiksaitis JK, Brennan DC, Fishman J, Allen U. Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant 2005; 5 ( 2 ): 218 – 227.; Ginaldi L, De Martinis M, D'Ostilio A, Marini L, Loreto MF, Quaglino D. Immunological changes in the elderly. Aging (Milano) 1999; 11 ( 5 ): 281 – 286.; Westall GP, Mifsud NA, Kotsimbos T. Linking CMV serostatus to episodes of CMV reactivation following lung transplantation by measuring CMV-specific CD8+ T-cell immunity. Am J Transplant 2008; 8 ( 8 ): 1749 – 1754.

الاتاحة: https://hdl.handle.net/2027.42/73013
http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=19735385&dopt=citation
https://doi.org/10.1111/j.1399-3062.2009.00443.x

المؤلفون: Pogue, J. M., DePestel, Daryl D., Kaul, D. R., Khaled, Y., Frame, D. G.

المساهمون: Department of Pharmacy Services, Sinai Grace Hospital, Detroit Medical Center, Detroit, Michigan, USA, Department of Clinical, Social, and Administrative Sciences, University of Michigan College of Pharmacy, Ann Arbor, Michigan, USA, Department of Pharmacy Services, University of Michigan Health System, Ann Arbor, Michigan, USA, Department of Internal Medicine, Division of Infectious Diseases, University of Michigan Medical School, Ann Arbor, Michigan, USA, Blood and Marrow Transplantation Program, University of Michigan Health System, Ann Arbor, Michigan, USA

مصطلحات موضوعية: Clostridium Difficile, CDAD, Vancomycin, GVHD, Graft-versus-Host Disease, Peripheral Blood Stem Cell Transplant, Medicine (General), Microbiology and Immunology, Health Sciences

وصف الملف: 96617 bytes; 3109 bytes; application/pdf; text/plain

Relation: Pogue, J.M.; DePestel, D.D.; Kaul, D.R.; Khaled, Y.; Frame, D.G. (2009). "Systemic absorption of oral vancomycin in a peripheral blood stem cell transplant patient with severe graft-versus-host disease of the gastrointestinal tract." Transplant Infectious Disease 11(5): 467-470.; https://hdl.handle.net/2027.42/74898; http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=19638004&dopt=citation; Transplant Infectious Disease; Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile -associated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45: 302 – 307.; 2. Product information. Vancocin (vancomycin hydrochloride capsules, USP pulvules). Indianapolis, IN: Eli Lilly and Company, 2000.; Spitzer PG, Eliopoulos GM. Systemic absorption of enteral vancomycin in a patient with pseudomembranous colitis. Ann Intern Med 1984; 100 ( 4 ): 533 – 534.; Matzke GR, Halstenson CE, Olson PL, Collins AJ, Abraham PA. Systemic absorption of oral vancomycin in patients with renal insufficiency and antibiotic-associated colitis. Am J Kidney Dis 1987; 5: 422 – 425.; Armstrong CJ, Wilson TS. Systemic absorption of vancomycin. J Clin Pathol 1995; 48: 689.; Tedesco F, Markham R, Gurwith M, Christie D, Bartlett JG. Oral vancomycin for antibiotic-associated pseudomembranous colitis. Lancet 1978; 2: 226 – 228.; Dudley MN, Quintiliani R, Nightingale, Gontarz N. Absorption of vancomycin. Ann Intern Med 1984; 101: 144.; Aradhyula S, Manian FA, Hafidh SA, Bhutto SS, Alpert MA. Significant absorption of oral vancomycin in a patient with Clostridium difficile colitis and normal renal function. South Med J 2005; 99 ( 5 ): 518 – 520.; Fekely R, Silva J, Kauffman, Buggy B, Deery HG. Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. Am J Med 1989; 86 ( 1 ): 15 – 19.; Osawa R, Kaka A. Maculopapular rash induced by oral vancomycin. Clin Infect Dis 2008; 47: 880 – 881.; Bailey P, Gray H. An elderly woman with “Red Man Syndrome” in association with oral vancomycin therapy: a case report. Cases J 2008; 1: 111.; Leisenring WM, Martin PJ, Petersdorf EW, et al. An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens. Blood 2006; 108 ( 2 ): 749 – 755.; Kelly C, LaMont JT. Clostridium difficile – more difficult than ever. N Engl J Med 2008; 359: 1932 – 1940.

الاتاحة: https://hdl.handle.net/2027.42/74898
http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=19638004&dopt=citation
https://doi.org/10.1111/j.1399-3062.2009.00426.x

المؤلفون: Kaul, D. R., Lowe, Lori, Visvesvara, G. S., Farmen, S., Khaled, Y. A., Yanik, Gregory A.

المساهمون: Department of Internal Medicine, Division of Infectious Diseases and University of Michigan Medical School, Ann Arbor, Michigan, USA, Department of Pathology and Dermatology, University of Michigan Medical School, Ann Arbor, Michigan, USA, Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan, USA and, Blood and Bone Marrow Transplant Program, University of Michigan Medical School, Ann Arbor, Michigan, USA, Division of Parasitology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA

مصطلحات موضوعية: Acanthamoeba, Protozoa, Graft-versus-Host Disease, Voriconazole, Medicine (General), Microbiology and Immunology, Health Sciences

وصف الملف: 1194969 bytes; 3109 bytes; application/pdf; text/plain

Relation: Kaul, D.R.; Lowe, L.; Visvesvara, G.S.; Farmen, S.; Khaled, Y.A.; Yanik, G.A. (2008). " Acanthamoeba infection in a patient with chronic graft-versus-host disease occurring during treatment with voriconazole." Transplant Infectious Disease 10(6): 437-441.; https://hdl.handle.net/2027.42/74744; http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=18713138&dopt=citation; Transplant Infectious Disease; Cha JH, Furie K, Kay J, Walensky RP, Mullins ME, Hedley-Whyte ET. Case records of the Massachusetts General Hospital. Case 39-2006. A 24-year-old woman with systemic lupus erythematosus, seizures, and right arm weakness. N Engl J Med 2006; 355: 2678 – 2689.; Marciano-Cabral F, Cabral G. Acanthamoeba spp. as agents of disease in humans. Clin Microbiol Rev 2003; 16: 273 – 307.; Anderlini P, Przepiorka D, Luna M, et al. Acanthamoeba meningoencephalitis after bone marrow transplantation. Bone Marrow Transplant 1994; 14: 459 – 461.; Feingold JM, Abraham J, Bilgrami S, et al. Acanthamoeba meningoencephalitis following autologous peripheral stem cell transplantation. Bone Marrow Transplant 1998; 22: 297 – 300.; Gardner HA, Martinez AJ, Visvesvara GS, Sotrel A. Granulomatous amebic encephalitis in an AIDS patient. Neurology 1991; 41: 1993 – 1995.; Gordon SM, Steinberg JP, DuPuis MH, Kozarsky PE, Nickerson JF, Visvesvara GS. Culture isolation of Acanthamoeba species and leptomyxid amebas from patients with amebic meningoencephalitis, including two patients with AIDS. Clin Infect Dis 1992; 15: 1024 – 1030.; Murakawa GJ, McCalmont T, Altman J, et al. Disseminated acanthamebiasis in patients with AIDS. A report of five cases and a review of the literature. Arch Dermatol 1995; 131: 1291 – 1296.; Seijo Martinez M, Gonzalez-Mediero G, Santiago P, et al. Granulomatous amebic encephalitis in a patient with AIDS: isolation of Acanthamoeba sp. Group II from brain tissue and successful treatment with sulfadiazine and fluconazole. J Clin Microbiol 2000; 38: 3892 – 3895.; Castellano-Sanchez A, Popp AC, Nolte FS, et al. Acanthamoeba castellani encephalitis following partially mismatched related donor peripheral stem cell transplantation. Transpl Infect Dis 2003; 5: 191 – 194.; Hunt SJ, Reed SL, Mathews WC, Torian B. Cutaneous Acanthamoeba infection in the acquired immunodeficiency syndrome: response to multidrug therapy. Cutis 1995; 56: 285 – 287.; Nachega JB, Rombaux P, Weynand B, Thomas G, Zech F. Successful treatment of Acanthamoeba rhinosinusitis in a patient with AIDS. AIDS Patient Care STDS 2005; 19: 621 – 625.; Oliva S, Jantz M, Tiernan R, Cook DL, Judson MA. Successful treatment of widely disseminated acanthamoebiasis. South Med J 1999; 92: 55 – 57.; Schuster FL, Guglielmo BJ, Visvesvara GS. In-vitro activity of miltefosine and voriconazole on clinical isolates of free-living amebas: Balamuthia mandrillaris, Acanthamoeba spp., and Naegleria fowleri. J Eukaryot Microbiol 2006; 53: 121 – 126.; Sison JP, Kemper CA, Loveless M, McShane D, Visvesvara GS, Deresinski SC. Disseminated acanthamoeba infection in patients with AIDS: case reports and review. Clin Infect Dis 1995; 20: 1207 – 1216.; Walia R, Montoya JG, Visvesvera GS, Booton GC, Doyle RL. A case of successful treatment of cutaneous Acanthamoeba infection in a lung transplant recipient. Transpl Infect Dis 2007; 9: 51 – 54.; Walochnik J, Aichelburg A, Assadian O, et al. Granulomatous amoebic encephalitis caused by Acanthamoeba amoebae of genotype t2 in a human immunodeficiency virus-negative patient. J Clin Microbiol 2008; 46: 338 – 340.; Bloch KC, Schuster FL. Inability to make a premortem diagnosis of Acanthamoeba species infection in a patient with fatal granulomatous amebic encephalitis. J Clin Microbiol 2005; 43: 3003 – 3006.; Harwood CR, Rich GE, McAleer R, Cherian G. Isolation of Acanthamoeba from a cerebral abscess. Med J Aust 1988; 148: 47 – 49.; Calore EE, Cavaliere MJ, Calore NM. Cerebral amebiasis in the acquired immunodeficiency syndrome. Acta Neurol Belg 1997; 97: 248 – 250.; Koide J, Okusawa E, Ito T, et al. Granulomatous amoebic encephalitis caused by Acanthamoeba in a patient with systemic lupus erythematosus. Clin Rheumatol 1998; 17: 329 – 332.; Carter WW, Gompf SG, Toney JF, Greene JN, Cutolo EP. Disseminated Acanthamoeba sinusitis in a patient with AIDS: a possible role for early antiretroviral therapy. AIDS Read 2004; 14: 41 – 49.

الاتاحة: https://hdl.handle.net/2027.42/74744
http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=18713138&dopt=citation
https://doi.org/10.1111/j.1399-3062.2008.00335.x

المؤلفون: Nicolasora, N. P., Reddy, P., Kaul, D. R.

المساهمون: Department of Medicine, Division of Infectious Diseases, University of Michigan Medical School, Ann Arbor, Michigan, USA and, Blood and Bone Marrow Transplant Program, Department of Internal Medicine, Division of Hematology-Oncology, University of Michigan Medical School, Ann Arbor, Michigan, USA

مصطلحات موضوعية: Adenovirus, Diarrhea, Stem Cell Transplant, Low-dose Cidofovir, Medicine (General), Microbiology and Immunology, Health Sciences

وصف الملف: 728347 bytes; 3109 bytes; application/pdf; text/plain

Relation: Nicolasora, N.P.; Reddy, P.; Kaul, D.R. (2008). "Biopsy-proven adenoviral diarrhea responding to low-dose cidofovir." Transplant Infectious Disease 10(5): 346-350.; https://hdl.handle.net/2027.42/73090; http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=18282236&dopt=citation; Transplant Infectious Disease; Shields AF, Hackman RC, Fife KH, et al. Adenovirus infections in patients undergoing bone marrow transplantation. N Engl J Med 1985; 312: 529 – 533.; Flomenberg P, Babbitt J, Drobyski WR, et al. Increasing incidence of adenovirus disease in bone marrow transplant recipients. J Infect Dis 1994; 169: 775 – 781.; Blanke C, Clark C, Broun R, et al. Evolving pathogens in allogeneic bone marrow transplantation: increased fatal adenoviral infections. Am J Med 1995; 99: 326 – 368.; Munoz FM, Piedra PA, Demmler GJ. Disseminated adenovirus disease in immunocompromised and immunocompetent children. Clin Infect Dis 1998; 27: 1194 – 1200.; Hale GA, Heslop HE, Krance RA, et al. Adenovirus infection after pediatric bone marrow transplantation. Bone Marrow Transplant 1999; 23: 277 – 282.; Howard DS, Phillips GL, Reece DE, et al. Adenovirus infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 1999; 29: 1494 – 1501.; Baldwin A, Kingman H, Darville M, et al. Outcome and clinical course of 100 patients with adenovirus infection following bone marrow transplantation. Bone Marrow Transplant 2000; 26: 1333 – 1338.; Runde V, Ross S, Trenschel R, et al. Adenoviral infection after allogeneic stem cell transplantation: report on 130 patients from a single SCT unit involved in a prospective multicenter surveillance study. Bone Marrow Transplant 2001; 28: 51 – 57.; Hoffman JA, Shah AJ, Ross LA, et al. Adenoviral infections and a prospective trial of cidofovir in pediatric hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2001; 7: 388 – 394.; La Rosa AM, Champlin RE, Mirza N, et al. Adenovirus infections in adult recipients of blood and marrow transplants. Clin Infect Dis 2001; 32: 871 – 876.; Chakrabarti S, Mautner V, Osman H, et al. Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. Blood 2002; 100: 1619 – 1627.; Bruno B, Gooley T, Hackman RC, et al. Adenovirus infection in hematopoietic stem cell transplantation: effect of ganciclovir and impact on survival. Biol Blood Marrow Transplant 2003; 9: 341 – 352.; Lion T, Baumgartinger R, Watzinger F, et al. Molecular monitoring of adenovirus in peripheral blood after allogeneic bone marrow transplantation permits early diagnosis of disseminated disease. Blood 2003; 102: 1114 – 1120.; Humar A, Kumar D, Mazzulli T, et al. A surveillance study of adenovirus infection in adult solid-organ transplant recipients. Am J Transplant 2005; 5: 2555 – 2559.; Symeonidis N, Jakubowski A, Pierre-Louis S, et al. Invasive adenoviral infections in T-cell-depleted allogeneic hematopoietic stem cell transplantation: high mortality in the era of cidofovir. Transpl Infect Dis 2007; 9: 108 – 113.; Walls T, Hawrami K, Ushiro-Lumb I, et al. Adenovirus infection after pediatric bone marrow transplantation: is treatment always necessary? Clin Infect Dis 2005; 40: 1244 – 1249.; Kampmann B, Cubitt D, Walls T, et al. Improved outcome for children with disseminated adenoviral infection following allogeneic stem cell transplantation. Br J Haematol 2005; 130: 595 – 603.; Legrand F, Berrebi D, Houhou N, et al. Early diagnosis of adenovirus infection and treatment with cidofovir after bone marrow transplantation in children. Bone Marrow Transplant 2001; 27: 621 – 626.; Neofytos D, Ojhal A, Mokerjee B, et al. Treatment of adenovirus disease in stem cell transplant recipients with cidofovir. Biol Blood Marrow Transplant 2007; 13: 74 – 81.; Ljungman P, Ribaud P, Eyrich M, et al. Cidofovir for adenovirus infections after allogeneic hematopoietic stem cell transplantation: a survey by the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2003; 31: 4816.; Leruez-Ville M, Minard V, Lacaille F, et al. Real-time blood plasma polymerase chain reaction for management of disseminated adenovirus infection. Clin Infect Dis 2004; 38: 45 – 52.; Muller WJ, Levin MJ, Shin YK, et al. Clinical and in vitro evaluation of cidofovir for treatment of adenovirus infection in pediatric hematopoietic stem cell transplant recipients. Clin Infect Dis 2005; 41: 1812 – 1816.; Hatakeyama N, Suzuki N, Kudoh T, et al. Successful cidofovir treatment of adenovirus-associated hemorrhagic cystitis and renal dysfunction after allogenic bone marrow transplant. Pediatr Infect Dis J 2003; 22: 928 – 929.; Nagafuji K, Aoki K, Henzan H, et al. Cidofovir for treating adenoviral hemorrhagic cystitis in hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2004; 34: 909 – 914.; Ison MG. Adenovirus infections in transplant recipients. Clin Infect Dis 2006; 43: 331 – 339.; Chakrabarti S, Collingham KE, Stevens RH, et al. Isolation of viruses from stools in stem cell recipients: prospective surveillance study. Bone Marrow Transplant 2000; 25: 277 – 182.; Cox GJ, Matsui SM, Lo RS, et al. Etiology and outcome of diarrhea after marrow transplantation: a prospective study. Gastroenterology 1994; 107: 1398 – 1407.; Chakrabarti S, Collingham KE, Fegan CD, et al. Adenovirus infections following haematopoietic cell transplantation: is there a role for adoptive immunotherapy? Bone Marrow Transplant 2000; 26: 305 – 307.; Avivi I, Chakrabarti S, Milligan DW, et al. Incidence and outcome of adenovirus disease in transplant recipients after reduced-intensity conditioning with alemtuzumab. Biol Blood Marrow Transplant 2004; 10: 186 – 194.; Feuchtinger T, Lucke J, Hamprecht K, et al. Detection of adenovirus-specific T cells in children with adenovirus infection after allogeneic stem cell transplantation. Br J Haematol 2005; 128: 503 – 509.; Heemskerk B, Lankester AC, van Vreeswijk T, et al. Immune reconstitution and clearance of human adenovirus viremia in pediatric stem-cell recipients. J Infect Dis 2005; 191: 520 – 530.; Hromas R, Cornetta K, Srour E, Blanke C, Broun ER. Donor leukocyte infusion as therapy of life-threatening adenoviral infections after T-cell-depleted bone marrow transplantation. Blood 1994; 84: 1689 – 1690.

الاتاحة: https://hdl.handle.net/2027.42/73090
http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=18282236&dopt=citation
https://doi.org/10.1111/j.1399-3062.2008.00303.x

المؤلفون: Kusne, S., Taranto, S., Covington, S., Kaul, D. R., Blumberg, E. A., Wolfe, C., Green, M.

المصدر: American Journal of Transplantation; December 2016, Vol. 16 Issue: 12 p3562-3567, 6p

المؤلفون: Kaul, D. R., Stoelben, S., Cober, E., Ojo, T., Sandusky, E., Lischka, P., Zimmermann, H., Rubsamen‐Schaeff, H.

المصدر: American Journal of Transplantation; May 2011, Vol. 11 Issue: 5 p1079-1084, 6p